Roche and Chiasma Sign $585 Million Deal

Roche has teamed up with Chiasma to develop and market Octreolin, Chiasma’s investigational treatment for growth hormone disorders. Octreolin is oral form of the peptide octreotide, a somatostatin analogue which is currently only commercially available by injection and is marketed by Novartis as Sandostatin.  The drug is currently in a Phase III clinical trial for

Continue Reading

Roche Set Up Swiss Academic Translational Centre

Roche yesterday announced that they are increasing their collaborative efforts with academic researchers to deliver the next generation of targeted therapies for unmet medical needs by creating an external academic translational research hub in their home market. The hub in Zurich, Switzerland will be four-way collaboration between Roche, ETH (the Swiss Federal Institute of Technology)

Continue Reading